10-K: RenovoRx Reports 2025 Revenue Growth, Advances Pancreatic Cancer Trial

RenovoRx, a life sciences company, reported $1.1 million in RenovoCath sales for 2025 and continued progress in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer.

Summary

• Generated $1.1 million in revenue from RenovoCath sales for the year ended December 31, 2025, a significant increase from $43,000 in 2024.
• 12 U.S. cancer centers are utilizing RenovoCath commercially, with 21 additional centers evaluating or preparing for activation, tripling the potential near-term commercial centers in the sales pipeline since Q1 2025.
• The Phase III TIGeR-PaC trial for IAG (intra-arterial delivery of gemcitabine via RenovoCath) in locally advanced pancreatic cancer (LAPC) is ongoing, with 104 patients randomized and 72 events occurred as of March 24, 2026.
• Enrollment for the TIGeR-PaC trial is anticipated to be completed by mid-2026, with final data expected in 2027.
• The first interim analysis (March 2023) of the TIGeR-PaC trial showed a 6-month median Overall Survival (OS) benefit (nearly a 60% improvement) and a greater than 65% reduction in adverse events for IAG versus the study control arm.
• The second interim analysis (Q2 2025) recommended continuation of the trial without modification, though the company elected to defer publishing the interim data to avoid compromising trial integrity.
• RenovoCath with gemcitabine (IAG) received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon New Drug Application (NDA) approval by the FDA.
• The initial target market for RenovoCath is estimated at approximately $400 million in peak annual U.S. sales, with potential expansion opportunities across other clinical indications creating a multi-billion-dollar total addressable market.
• The company incurred net losses of $11.2 million in 2025 and $8.8 million in 2024, with an accumulated deficit of $61.4 million as of December 31, 2025.
• An additional $10.0 million in gross proceeds was raised through a private placement offering completed in March 2026.
• Material weaknesses in internal control over financial reporting identified for 2025 and 2024 have been remediated as of December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to significant revenue growth from RenovoCath sales and encouraging interim clinical trial data for IAG, despite ongoing net losses and Nasdaq compliance issues. The remediation of internal control weaknesses is also a positive governance step.

Positives

• Significant revenue growth from RenovoCath sales: $1.1 million in 2025 compared to $43,000 in 2024, representing a 2512% increase.
• Growing commercial adoption of RenovoCath: 12 U.S. cancer centers are utilizing the device commercially, with 21 additional centers evaluating or preparing for activation, tripling the sales pipeline since Q1 2025.
• Positive first interim analysis of the Phase III TIGeR-PaC trial showed a 6-month median Overall Survival (OS) benefit (nearly 60% improvement) and a greater than 65% reduction in adverse events for IAG versus the standard of care.
• The Data Monitoring Committee (DMC) recommended continuation of the TIGeR-PaC trial after both the first and second interim analyses, indicating confidence in the trial's progress and safety profile.
• IAG received Orphan Drug Designation for pancreatic and bile duct cancer, which provides 7 years of market exclusivity upon NDA approval.
• Pre-clinical data published in July 2024 demonstrated up to 100 times higher local drug concentration with TAMP compared to systemic chemotherapy.
• Pharmacokinetic data presented at ASCO GI 2026 and SSO 2025 Annual showed lower systemic levels of gemcitabine with TAMP treatment, supporting the potential for decreased systemic side effects.
• An existing reimbursement code with the Centers for Medicare and Medicaid Services covers specialty pressure-mediated delivery catheters, creating incentives for hospital adoption of RenovoCath.
• The company established the RenovoCath Medical Advisory Board in February 2026 to provide strategic clinical insights and advance the TAMP therapy platform.
• Remediation of previously identified material weaknesses in internal control over financial reporting was completed as of December 31, 2025.

Negatives

• Continued significant net losses: $11.2 million in 2025 and $8.8 million in 2024.
• Accumulated deficit of $61.4 million as of December 31, 2025.
• The company's operating history as a revenue-generating company is limited, and the commercial prospects for its novel therapy platform are unproven and uncertain.
• The company elected to defer publishing the actual second interim data from the TIGeR-PaC trial to avoid compromising trial integrity.
• Reliance on a single-source contract manufacturer (Medical Murray, Inc.) for RenovoCath, posing potential supply chain risks.
• The company is not in compliance with Nasdaq's minimum bid price requirement ($1.00 per share) as of December 31, 2025.
• Selling, general and administrative expenses increased by approximately $2.1 million (41%) year-over-year.
• Uncertainty regarding FDA agreement with the Modified Statistical Analysis Plan (SAP) for the TIGeR-PaC trial.
• The company expects to continue incurring net losses until FDA approval for IAG or until RenovoCath commercial sales generate sufficient revenues to offset expenses.

Risks

• No drug/device combination products approved for commercial sale; limited experience in standalone medical device commercialization and no extended operating history as a revenue-generating company.
• Incurred significant net losses in each period since inception and expects to continue incurring net losses until FDA approval for IAG or sufficient RenovoCath revenues.
• Commercial strategy for selling RenovoCath as a standalone device is a relatively new activity and subject to significant inherent risks (manufacturing, supply chain, sales and marketing efforts).
• Estimates of total addressable market, potential revenues, and similar metrics related to RenovoCath commercialization efforts may prove inaccurate.
• Revenue recognition from RenovoCath commercialization activities could be complex and uncertain, potentially requiring deferral of revenues.
• Revenues and results of operations, particularly from RenovoCath sales, are difficult to predict and may fluctuate substantially from quarter to quarter.
• May need to raise additional capital over the longer term to develop and commercialize IAG and expand RenovoCath sales; failure to obtain funding may delay/eliminate programs or threaten going concern status.
• Commercial viability of IAG or other product candidates remains subject to current and future preclinical studies, clinical trials (notably Phase III TIGeR-PaC), and regulatory approvals.
• Failure of the Phase III TIGeR-PaC study to achieve results conducive to progressing the study or filing and receiving NDA approval would cause significant harm.
• Failure to achieve projected commercial or development goals in announced timeframes could lead to a decline in stock price.
• Product candidates may exhibit undesirable side effects, delaying or precluding further development or regulatory approval or limiting their use if approved.
• Negative results from preclinical studies or clinical trials could delay or preclude further development or commercialization.
• Inability to satisfy regulatory requirements may prevent commercialization of product candidates.
• Inability of product candidates to compete effectively with marketed drugs targeting similar indications.
• May delay or terminate the development of product candidates if the perceived market or commercial opportunity does not justify further investment.
• Future success depends on the ability to retain key personnel and to attract, retain, and motivate qualified personnel, especially in a hyper-competitive compensation environment.
• Inability to protect intellectual property effectively, potentially allowing third parties to use technologies and impairing competitive advantage.
• Issued patents may not be broad enough, or competitors may develop more effective technologies, designs, or methods without infringing intellectual property rights.
• Not currently in compliance with Nasdaq's minimum bid price continued listing requirement, risking delisting.
• Business disruptions (e.g., earthquakes, power shortages, cybersecurity threats, natural disasters, geopolitical events) could seriously harm future revenue and financial condition and increase costs.
• Reliance on a single-source contract U.S. manufacturer (Medical Murray, Inc.) for the RenovoCath component.
• Compliance with extensive and rigorous government regulations by foreign regulatory agencies and the FDA, including healthcare fraud and abuse laws, is complex and failure could lead to substantial enforcement actions.
• Healthcare reform measures (e.g., Inflation Reduction Act, GENEROUS Model, TrumpRx) could adversely affect the business, particularly drug pricing and reimbursement.
• Reimbursement for any approved products may be limited or unavailable, making it difficult to sell profitably.
• Legal proceedings or claims against the company could be costly and time-consuming to defend and harm reputation.
• Changes in tax laws or in their implementation or interpretation may adversely affect business and financial condition.
• Ability to use net operating losses (NOLs) to offset future taxable income may be subject to certain limitations under Section 382 and 383 of the Internal Revenue Code.
• Security threats to information technology infrastructure and/or physical buildings could expose the company to liability and damage its reputation and business.
• A variety of risks associated with operating internationally could materially adversely affect the business.
• General economic or business conditions may have a negative impact on the business.
• The market price of common stock may be volatile and fluctuate substantially.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to product candidates on unfavorable terms.
• Risk of securities class action litigation.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research, the market price and trading volume could decline.
• No expectation to pay dividends in the foreseeable future; investors must rely on price appreciation.
• Increased costs and management time due to operating as a public company, especially after no longer qualifying as an emerging growth company.
• Material weaknesses in internal control over financial reporting (though remediated as of December 31, 2025) could cause loss of investor confidence.
• Anti-takeover and other provisions in corporate documents and Delaware law could impair a takeover attempt and impact corporate governance.
• Designation of the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company anticipates completing enrollment for its Phase III TIGeR-PaC trial by mid-2026, with final data expected in 2027. It expects to grow revenue from RenovoCath commercial sales in 2026 and continues to explore expansion opportunities for RenovoCath across other clinical indications, potentially creating a multi-billion-dollar total addressable market. The company also plans to pursue an FDA New Drug Application (NDA) filing for IAG in the coming years, assuming study endpoints are met, and may expand its development pipeline into additional cancer tumors.

Management Comments

• "We are a commercial-stage growth company commercializing RenovoCath in the United States, have received our first commercial purchase orders for RenovoCath devices in December 2024."
• "The growing adoption reflects increasing clinical demand for RenovoCath as it becomes integrated into overall cancer treatment paradigms and sets the stage potential revenue expansion in 2026."
• "We believe the initial target market for RenovoCath would be approximately $400 million in peak annual U.S. sales, based on our internal assumptions."
• "We believe there are expansion opportunities across other clinical indications that could ultimately create a multi-billion-dollar total addressable market potential for RenovoCath."
• "The change to the 80% power calculation aligns with common practice for clinical trials and we believe this design will shorten the timeframe needed to complete the study, as well as significantly decrease our costs."
• "To avoid compromising the integrity of the trial with the FDA, and after discussions with the DMC and consultation with our regulatory advisors, we elected to defer publishing the interim data."
• "RenovoRx will revisit publishing the actual second interim data, most likely upon completion of the study as is common for Phase III trials."
• "TIGeR-PaC remains the cornerstone of our clinical development program, validating its mechanism of action and safety profile through rigorous, long-term evaluation."
• "We anticipate completion of enrollment by the middle of 2026, ensuring a minimum of 114 patients will be randomized. Final data in the study is anticipated in 2027."
• "Management has completed the implementation of these remedial measures and, based on testing of the design and operating effectiveness of the remediated controls, concluded that the previously identified material weaknesses were remediated as of December 31, 2025."

Industry Context

StockSavvy.ai notes that RenovoRx operates in a highly competitive oncology market, with established pharmaceutical and biotechnology companies, as well as academic institutions, developing new therapies. The company's focus on targeted drug delivery via its TAMP platform and RenovoCath device positions it within a niche aiming to reduce systemic toxicities and improve efficacy, a common objective in chemotherapy innovation. Recent FDA approvals like Novocure's Optune Pax for LAPC and promising topline results from Revolution Medicines' Daraxonrasib plus GnP combination highlight the dynamic landscape and the continuous evolution of standard of care treatments. RenovoRx's strategy to commercialize RenovoCath as a standalone device while pursuing IAG approval aligns with broader trends of leveraging existing technologies for new applications and indications, but faces competition from both systemic and other interventional approaches.

Comparison to Industry Standards

• The TIGeR-PaC trial's first interim analysis showed a 6-month median Overall Survival (OS) benefit for IAG, representing nearly a 60% improvement over the study control arm (IV administration of gemcitabine and nab-paclitaxel). This compares favorably to previous large randomized clinical trials not sponsored by RenovoRx, where the expected median OS for LAPC patients receiving only IV systemic chemotherapy or IV chemotherapy plus radiation (standard of care) is 12.0 to 18.8 months.
• Patients in the TIGeR-PaC trial's IAG arm also experienced a greater than 65% reduction in adverse events compared to the standard of care, suggesting a better safety profile.
• Preclinical data published in the Journal of Vascular Interventional Radiology (July 2024) demonstrated up to 100 times higher local drug concentration with TAMP compared to systemic chemotherapy, indicating a significant advantage in targeted delivery.
• Pharmacokinetic data presented at ASCO GI 2026 and SSO 2025 Annual showed lower systemic levels of gemcitabine with TAMP treatment despite a 50% higher drug concentration during infusion compared to intravenous gemcitabine, supporting the potential for reduced systemic side effects.
• In comparison to competitors, Novocure's Optune Pax, recently FDA approved for LAPC, showed a 2.04-month median overall survival difference when concomitant with gemcitabine and nab-paclitaxel, which is less than the 6-month benefit observed in RenovoRx's first interim analysis for IAG. Revolution Medicines' Daraxonrasib plus GnP combination also showed promising topline results in 1L Metastatic PDAC, indicating ongoing innovation in the field.
• The company's initial target market for RenovoCath of approximately $400 million in peak annual U.S. sales, with potential for multi-billion dollar expansion, suggests a significant market opportunity if penetration goals are met, leveraging existing reimbursement codes for specialty pressure-mediated delivery catheters.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings, and no such litigation is currently pending or threatened. It may become involved in various legal actions in the ordinary course of business, but none are expected to have a material adverse effect.

Related Party Transactions

• Dr. Ramtin Agah, Chief Medical Officer and Executive Chairman, received consulting fees of $337,000 in 2025 (compared to $303,000 in 2024) and discretionary bonuses of $121,000 in 2025 (compared to $49,000 in 2024).
• Five directors, officers, or employees participated as 'Insiders' in the March 2026 private placement, purchasing shares and warrants at a slightly higher price ($1.0288 per share and related Milestone Warrant) than non-affiliated institutional investors ($0.938 per share).

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises and warrant exercises. Risk of stock price volatility due to clinical trial outcomes, commercialization efforts, and Nasdaq compliance issues. Positive clinical data and commercial growth could increase shareholder value.
• Employees: Increased headcount and competitive compensation environment. Equity incentive plans aim to attract, retain, and reward personnel.
• Customers (Cancer Centers/Physicians): Growing adoption of RenovoCath indicates increasing clinical demand and satisfaction. Potential for improved patient outcomes with TAMP therapy.
• Patients: Potential for increased safety, tolerance, and improved efficacy in cancer treatment, particularly for LAPC, through targeted drug delivery. Orphan Drug Designation aims to address unmet medical needs.
• Suppliers: Reliance on a single-source manufacturer (Medical Murray, Inc.) for RenovoCath poses supply chain risks.
• Creditors: Ongoing net losses and the need for future capital raises indicate potential reliance on debt financing, impacting creditors.

Next Steps

• Complete enrollment for Phase III TIGeR-PaC trial by mid-2026.
• Anticipate final data from TIGeR-PaC study in 2027.
• Pursue FDA New Drug Application (NDA) filing for IAG in the coming years, assuming study endpoints are met.
• Expand commercial sales operations for RenovoCath, including hiring additional sales and marketing personnel.
• Advance clinical development of IAG and the TAMP platform, including expanding the post-marketing RR5 Study and exploring other preclinical and clinical pipeline indication opportunities.
• Maintain, expand, enforce, defend, and protect the intellectual property portfolio, including exploring additional patent opportunities through 2045.
• Continue to monitor and evaluate the effects of additional guidance or interpretive regulations issued in connection with the One Big Beautiful Bill Act (OBBBA).
• Address Nasdaq minimum bid price non-compliance by the end of June 2026, potentially considering a reverse stock split.
• Evaluate reliance on third-party Contract Development and Manufacturing Organizations (CDMOs) and research partners due to the BIOSECURE Act.

Key Dates

Recommendation

The filing presents a mixed bag of significant progress and substantial risks. The strong revenue growth from RenovoCath sales and the encouraging interim clinical data from the TIGeR-PaC trial are positive indicators and suggest potential for future value creation. The remediation of internal control weaknesses is also a positive step for governance. However, the company continues to incur significant net losses, has a substantial accumulated deficit, and faces ongoing liquidity challenges requiring future capital raises, which will likely cause further dilution. The Nasdaq minimum bid price non-compliance adds a layer of uncertainty. While the long-term potential of the TAMP platform is compelling, the early stage of commercialization, reliance on a single manufacturer, and inherent risks of clinical development and regulatory approval warrant a cautious approach. A 'hold' recommendation reflects the balance between promising developments and considerable operational and financial risks, suggesting investors monitor progress closely before making further commitments.

Keywords

RenovoRx, RNXT, oncology, pancreatic cancer, cholangiocarcinoma, drug-device combination, RenovoCath, TAMP therapy, intra-arterial delivery, gemcitabine, Phase III clinical trial, TIGeR-PaC, Orphan Drug Designation, medical device, biopharmaceutical, SEC filing, 10-K, financial results, clinical development, targeted therapy, cancer treatment, FDA clearance, Nasdaq compliance, capital raise